AARTIDRUGSPharmaceuticals
Aarti Drugs Ltd — Profit & Loss Statement
₹319.75
-3.05%
Aarti Drugs Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.39 Cr | -0.41 Cr | — |
| Tax Rate For Calcs | 0.21 | 0.27 | 0.26 | 0.24 | — |
| Normalized EBITDA | 303.42 Cr | 320.50 Cr | 309.33 Cr | 342.44 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -1.53 Cr | -1.69 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -1.53 Cr | -1.69 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 168.16 Cr | 171.42 Cr | 166.31 Cr | 205.04 Cr | — |
| Reconciled Depreciation | 55.78 Cr | 51.45 Cr | 50.32 Cr | 50.05 Cr | — |
| Reconciled Cost Of Revenue | 1.54K Cr | 1.68K Cr | 2.22K Cr | 1.98K Cr | — |
| EBITDA | 303.42 Cr | 320.50 Cr | 307.80 Cr | 340.75 Cr | — |
| EBIT | 247.64 Cr | 269.05 Cr | 257.48 Cr | 290.70 Cr | — |
| Net Interest Income | -35.87 Cr | -33.52 Cr | -36.44 Cr | -23.19 Cr | — |
| Interest Expense | 35.87 Cr | 33.52 Cr | 33.29 Cr | 20.75 Cr | — |
| Normalized Income | 168.16 Cr | 171.42 Cr | 167.44 Cr | 206.32 Cr | — |
| Net Income From Continuing And Discontinued Operation | 168.16 Cr | 171.42 Cr | 166.31 Cr | 205.04 Cr | — |
| Total Expenses | 2.16K Cr | 2.26K Cr | 2.44K Cr | 2.19K Cr | — |
| Diluted Average Shares | 9.13 Cr | 9.19 Cr | 9.26 Cr | 9.26 Cr | — |
| Basic Average Shares | 9.13 Cr | 9.19 Cr | 9.26 Cr | 9.26 Cr | — |
| Diluted EPS | 18.35 | 18.56 | 17.97 | 22.14 | — |
| Basic EPS | 18.35 | 18.56 | 17.97 | 22.14 | — |
| Diluted NI Availto Com Stockholders | 168.16 Cr | 171.42 Cr | 166.31 Cr | 205.04 Cr | — |
| Net Income Common Stockholders | 168.16 Cr | 171.42 Cr | 166.31 Cr | 205.04 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 168.16 Cr | 171.42 Cr | 166.31 Cr | 205.04 Cr | — |
| Minority Interests | 0.06 Cr | -0.17 Cr | -0.05 Cr | 0.04 Cr | — |
| Net Income Including Noncontrolling Interests | 168.10 Cr | 171.59 Cr | 166.36 Cr | 205.00 Cr | — |
| Net Income Continuous Operations | 168.10 Cr | 171.59 Cr | 166.36 Cr | 205.00 Cr | — |
| Tax Provision | 43.67 Cr | 63.94 Cr | 57.82 Cr | 64.96 Cr | — |
| Pretax Income | 211.77 Cr | 235.53 Cr | 224.18 Cr | 269.96 Cr | — |
| Other Non Operating Income Expenses | 16.36 Cr | 4.03 Cr | -4.20 Cr | -4.56 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -1.53 Cr | -1.69 Cr | — |
| Net Non Operating Interest Income Expense | -35.87 Cr | -33.52 Cr | -36.44 Cr | -23.19 Cr | — |
| Interest Expense Non Operating | 35.87 Cr | 33.52 Cr | 33.29 Cr | 20.75 Cr | — |
| Operating Income | 231.28 Cr | 265.01 Cr | 266.35 Cr | 297.80 Cr | — |
| Operating Expense | 613.65 Cr | 585.85 Cr | 216.62 Cr | 205.87 Cr | — |
| Other Operating Expenses | 445.77 Cr | 432.06 Cr | 0.62 Cr | 0.32 Cr | — |
| Depreciation And Amortization In Income Statement | 55.78 Cr | 51.45 Cr | 50.32 Cr | 50.05 Cr | — |
| Depreciation Income Statement | 55.78 Cr | 51.45 Cr | 50.26 Cr | 50.01 Cr | — |
| Gross Profit | 844.93 Cr | 850.86 Cr | 482.97 Cr | 503.66 Cr | — |
| Cost Of Revenue | 1.54K Cr | 1.68K Cr | 2.22K Cr | 1.98K Cr | — |
| Total Revenue | 2.39K Cr | 2.53K Cr | 2.71K Cr | 2.49K Cr | — |
| Operating Revenue | 2.39K Cr | 2.53K Cr | 2.71K Cr | 2.49K Cr | — |
| Interest Income | — | 2.50 Cr | 0.70 Cr | 0.72 Cr | 2.60 Cr |
| Rent Expense Supplemental | — | 0.06 Cr | 0.06 Cr | 0.06 Cr | 0.06 Cr |
| Other Special Charges | — | 0.18 Cr | — | — | -3.27 Cr |
| Write Off | — | 2.19 Cr | 1.53 Cr | 1.69 Cr | 3.89 Cr |
| Total Other Finance Cost | — | 4.37 Cr | 3.84 Cr | 3.16 Cr | 3.27 Cr |
| Interest Income Non Operating | — | 2.50 Cr | 0.70 Cr | 0.72 Cr | 2.60 Cr |
| Amortization | — | 0.40 Cr | 0.06 Cr | 0.04 Cr | 1.18 Cr |
| Selling General And Administration | — | 71.87 Cr | 83.59 Cr | 81.59 Cr | 74.46 Cr |
| Selling And Marketing Expense | — | 57.69 Cr | 69.81 Cr | 68.36 Cr | 65.02 Cr |
| General And Administrative Expense | — | 14.18 Cr | 13.79 Cr | 13.23 Cr | 9.44 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Aarti Drugs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.